Finerenone in Type 1 Diabetes and CKD: Results from Phase 3 FINE-ONE Trial

The FINE-ONE phase 3 trial evaluated finerenone in adults with type 1 diabetes and CKD, finding a significant reduction in albuminuria compared to placebo. Hyperkalemia was the most common adverse event. These data provide new insights into management of type 1 diabetic kidney disease.

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.